Evolving treatment options in castration-resistant prostate cancer

Share :
Published: 6 Dec 2011
Views: 5001
Prof Kurt Miller, Dr Eleni Efstathiou, Dr Karim Fizazi and Dr Göran Ahlgren

Prof Miller chairs a review of data and expert opinion from EMCC 2011 and the First Prostate Cancer Debate 2011.  He opens the discussion with the observation that there have been many new developments in this area in the last 12 months which have changed our understanding of the disease and the way we treat it.  In light of these new developments, Dr Efstathiou talks about the evolving treatment landscape for patients with CRPC.  Drs Fizazi and Ahlgren go on to discuss the latest data from the Phase III study with androgen biosynthesis inhibitors and review the latest data on novel therapies and the potential impact on daily clinical practice.  Prof Miller concludes the discussion with the observation that we have entered a new era in COPC and CRPC, and therefore he will be coming back to ecancer.tv in a year’s time to discuss progression.


This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).